BioAtla Investor Presentation Deck

Encouraging Phase 1 results with Mecbotamab Vedotin (BA3011) in refractory NSCLC patients Maximum Change From Baseline (%) 100 80 60 40 20 0 -20 -40 -60 -80 -100 bicatla AXL - TmPS=0 1.5mg/kg d1,8 Response at Variable Dosing AXL-TmPS=0 1.2mg/kg d1,8 Not Evaluable 1.2mg/kg d1 Confirmed PR Stage IV adenocarcinoma (multiple chemo PKIs and pembrolizumab failure) AXL + TmPS-80 1.8mg/kg d1,8 A partial response was achieved in the AXL-high NSCLC patient refractory to multiple chemo PKIs and pembrolizumab failure BioAtla| Overview 17

View entire presentation